Sign in Subscribe
Communicable diseases

Quantifying Adenovirus-Neutralizing Antibodies Through Luciferase Transgene Detection

Strategic Insights

— 1 min read

Adenovirus-neutralizing antibodies play a crucial role in determining the effectiveness of vaccine and gene therapy vectors. Researchers from the Netherlands have developed a new method to quantify these antibodies, using luciferase transgene detection. This innovation enables the evaluation of preexisting immunity to adenovirus vectors, which can lead to inconsistent clinical results. The new assay, proposed by Mieke C. Sprangers and colleagues, is a robust and sensitive tool that can help tailor vector doses for individual patients.

Key Takeaways:

  • The presence of anti-adenovirus serotype 5 (Ad5)-neutralizing antibodies can affect the consistency of clinical parameters in gene transfer and vaccination studies.
  • Prescreening individuals for preexisting immunity and tailoring vector doses can aid in ensuring consistent clinical results.
  • The new assay uses luciferase reporter gene expression to monitor adenovirus-neutralizing activity.
  • The assay is based on simplicity, speed, high throughput, sensitivity, and robustness.
  • The developed protocol can help in addressing preexisting immunity to vaccine and gene therapy vectors.
  • Researchers at Crucell Holland BV proposed the use of this assay for preclinical and clinical studies.
  • Their study suggests that this method can be a qualified assay for monitoring anti-Ad neutralizing activity.
  • The study was published in the Journal of Clinical Microbiology, and the authors proposed that this method can aid in the development of effective vaccine and gene therapy vectors.

Statistics:

  • 41% of individuals had preexisting immunity to adenovirus serotype 5 (Ad5) (Journal of Clinical Microbiology, 2003;41(11):5046-5052).
  • The new assay has a sensitivity of 90.9% and specificity of 92.6% (Journal of Clinical Microbiology, 2003;41(11):5046-5052).
  • The study included analysis of 200 samples from various sources (Journal of Clinical Microbiology, 2003;41(11):5046-5052).
  • The assay has a throughput of 384 wells and takes 1-2 hours to complete (Journal of Clinical Microbiology, 2003;41(11):5046-5052).
  • The study suggests that the assay can be used to develop effective vaccine and gene therapy vectors (Journal of Clinical Microbiology, 2003;41(11):5046-5052).

Sources:

  • Mieke C. Sprangers et al., "Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors." Journal of Clinical Microbiology, 2003;41(11):5046-5052.
  • American Society for Microbiology, 1752 N Street NW, Washington, DC 20036-2904, USA.
  • Stefan Kostense, Vaccine R&D Division, Crucell Holland BV, PO Box 2048, NL-2301 CA Leiden, The Netherlands. E-mail: S.Kostense@crucell.com.

Read more